Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lantheus (LNTHResearch Report), Innate Pharma (IPHAResearch Report) and Olink Holding (OLKResearch Report) with bullish sentiments.

Lantheus (LNTH)

SVB Securities analyst Roanna Ruiz maintained a Buy rating on Lantheus today and set a price target of $120.00. The company’s shares closed last Monday at $57.25.

According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of -43.7% and a 12.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $107.75, a 91.6% upside from current levels. In a report issued on November 4, JonesTrading also maintained a Buy rating on the stock with a $104.00 price target.

See today’s best-performing stocks on TipRanks >>

Innate Pharma (IPHA)

SVB Securities analyst Daina Graybosch maintained a Buy rating on Innate Pharma today and set a price target of $9.00. The company’s shares closed last Monday at $2.48, close to its 52-week low of $1.92.

According to TipRanks.com, Graybosch has 0 stars on 0-5 stars ranking scale with an average return of -17.4% and a 32.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Molecular Partners, and LAVA Therapeutics.

Innate Pharma has an analyst consensus of Strong Buy, with a price target consensus of $10.83.

Olink Holding (OLK)

In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Olink Holding, with a price target of $27.00. The company’s shares closed last Monday at $20.68.

According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.4% and a 41.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Currently, the analyst consensus on Olink Holding is a Moderate Buy with an average price target of $22.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LNTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More